Leidos (LDOS) Q1 2026 Earnings Transcript

Leidos reported Q1 revenue of $4.4 billion, up 4% year over year, with adjusted EBITDA of $614 million and non-GAAP EPS of $3.13, while raising full-year 2026 revenue guidance by $500 million to $18.0 billion-$18.4 billion and EPS guidance to $12.10-$12.50. The Entrust acquisition is already accretive, the company generated $270 million of free cash flow, repurchased $200 million of stock, and reiterated strong pipeline momentum in defense, cyber, and health. Management also flagged near-term Q2 softness, but expects back-half improvement and continued accretion from synergies and portfolio reshaping.

Analysis

LDOS is turning into a rare case where portfolio refocusing, not just backlog, is driving multiple expansion potential. The key second-order effect is that management is converting cyclicality into a more visible mix of recurring mission software, cyber, and digitally enabled health work while simultaneously shedding or de-capitalizing lower-conviction assets; that should improve FCF durability and make the market pay up for the earnings stream. The incremental earnings boost from Entrust matters less than the signal that integration velocity is high and that cross-sell into energy infrastructure can create a self-reinforcing order cycle faster than investors model.

The market is likely underestimating the timing asymmetry here: Q2 looks like a digestion quarter, but the setup for Q3/Q4 is stronger if procurement normalizes and the new awards convert. That means the stock could de-rate on near-term guide skepticism before re-rating on visible booking acceleration; the best risk/reward is to own weakness into the quarter rather than chase strength. The most important catalyst is not revenue growth itself, but the combination of pipeline expansion plus margin stabilization in Defense and Homeland, which would remove the main bear case that mix and fixed-price issues are structurally impairing quality.

Contrarian view: the consensus will probably anchor on the optics of a lumpy guide and the SES restructuring noise, but that likely overstates near-term complexity and understates the option value of the new platform mix. If AI-enabled delivery is genuinely compressing cost and time-to-proposal across cyber, defense tech, and health, then LDOS can convert the same headcount into more bookings with less incremental working capital over the next 12-24 months. The main risk is that several of the growth pillars are still dependent on government timing, so any renewed procurement delay would push the re-rating out another quarter or two.

Key Decisions for Investors

• Go long LDOS on any post-earnings pullback over the next 2-6 weeks; target a 10-15% rebound if Q3/Q4 booking conversion confirms management’s pipeline narrative, with downside capped by resilient FCF and buybacks.
• Pair trade: long LDOS / short a lower-quality government services peer with weaker digital mix and heavier recomp risk over the next 3-6 months; thesis is LDOS deserves a premium for better capital allocation and higher cyber/health optionality.
• Buy LDOS Jan-2027 call spreads on weakness to express the back-half re-rating; risk/reward favors delayed upside because near-term volatility is likely from Q2 digestion and SES reporting noise.
• Add SES only as a relative-value short against LDOS if the market over-credits the JV transition before clarity on equity-method income; the transition likely suppresses transparency more than it unlocks value in the near term.
• Trim or hedge into any sharp 1-day rally until the market sees evidence that Defense/Homeland margins stabilize; the cleanest confirmation is sequential margin improvement rather than headline revenue growth.